BOWIE, Md., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Epilepsy Foundation announced today it has awarded $200,000 in funding for two…
Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma CLD-101 is Calidi’s novel allogeneic…
MALVERN, Pa., Sept. 30, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),…
Boca Raton, Florida, Sept. 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company…
Company to leverage capital and Valor’s expertise for strategic initiatives building market awareness, R&D roadmap, data analysis capabilities, and expanding…
GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary…
First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format KELOWNA, BC / ACCESSWIRE / September 27,…
Press release, Helsinki, 27 September 2024 at 10 AM (EEST) Nexstim Receives Order for NBS System 5 in Finland Nexstim…
As the global Alzheimer's community enters a new era of drug treatments, we at MTC are excited to announce our…
KANSAS CITY, Mo. and HEWLETT, N.Y. and PALO ALTO, Calif., Sept. 26, 2024 /PRNewswire/ -- The Brain Cancer Support and Solutions…